Agilon Health (AGL) Stock Still Looks Below Fair Value After Raised Guidance
agilon health has had an exceptionally strong run year to date, yet the stock still screens as undervalued on the broader checks, which raises a clear question about how much of the optimism is already in the price.
- Year to date, the share price is up about 412.2%, which puts recent volatility into sharp focus for anyone assessing what comes next.
- Recent membership growth and clinical initiatives can support expectations for future revenue, while any disappointment around how these programs translate into sustainable profitability remains a key risk for the valuation.
- On Simply Wall St's checks, agilon health looks cheap on most metrics, with a high value score of 5 out of 6, which suggests the broader set of valuation measures still leans in favor of the stock being undervalued.
The issue now is whether agilon health's recent surge has moved the stock ahead of its fundamentals, or if the valuation still leaves room for more upside.
Is agilon health Still Cheap on Sales?
P/S is usually a useful way to look at agilon health because the company is still working toward consistent free cash flow and earnings, so revenue is the cleaner anchor today.
On this measure, agilon health trades at a P/S ratio of about 0.2x, compared with a Healthcare industry average of roughly 1.4x and a peer group average near 2.2x. The Fair Ratio that blends factors like growth expectations, margins, size and risk sits closer to 0.4x. That indicates the current P/S is well below what this framework suggests for the business.
Despite the Q2 2026 update and higher revenue guidance, the market multiple still prices agilon health at a large discount to typical Healthcare peers on sales. For investors who focus on revenue-based metrics, the current gap between price and the Fair Ratio is notable.
On the P/S multiple, agilon health stock appears undervalued relative to both its tailored fair ratio and sector benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The agilon health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for agilon health pick up where the valuation puzzle leaves off by setting out the specific paths for revenue growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today's price. Instead of a single figure from a ratio or model, they describe the future that figure assumes so you can watch how agilon health's actual progress compares over time on the Community page.
The Simply Wall St community is split on agilon health, with one camp seeing meaningful upside and the other flagging valuation risk and execution challenges.
Bull case: 37% undervalued
"agilon's investments in advanced data analytics and AI-driven care management are beginning to deliver earlier identification and intervention for high-cost chronic conditions. This positions the company to outperform in cost containment and risk adjustment, yielding a step-change in medical margin and earnings in the medium term…"
Read the full Bull Case to see why agilon health could be undervalued
Bear case: 10% overvalued
"Volatility in payer negotiations, including a high dependence on a few large partners and the need to aggressively renegotiate contract economics for 50% of the membership in 2026, creates revenue concentration risk. It could result in further membership attrition or unfavorable terms that compress EBITDA and net income…"
Read the full Bear Case to see why agilon health could be overvalued
Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying!
The Bottom Line
agilon health still screens as undervalued on market multiples, even after a very strong year to date move, which keeps the valuation debate wide open. The core question is whether the current discount reflects temporary caution about execution or a more permanent pricing of membership and contract risks. Everything now hinges on how convincingly agilon health can turn membership growth and clinical programs into durable margins. If that translation into sustainable profitability stalls, the apparent discount could prove to be a value trap rather than an opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com